BioNexus Gene Lab Corp. was incorporated in Wyoming, USA in May 2017, and operates through its subsidiary (formerly BioNexus Gene Lab Sdn. Bhd., now MRNA Scientific Sdn. Bhd.) based in Kuala Lumpur, Malaysia. The company is active across Southeast Asia, with infrastructure supporting diagnostics, genomic screening and plans to grow into biologics manufacturing and contract development and manufacturing services. BGLC positions itself as a provider of advanced molecular diagnostics, non-invasive liquid biopsy tests, and genomic services aimed at improving early detection, disease monitoring and patient management.

More recently, the company has outlined ambitions to expand its business model to include CDMO services, biologics production and assay manufacturing — signalling a move toward integrated healthcare services combining diagnostics, development and manufacturing capabilities.

Key Products and Services

VitaGuard™ MRD Platform: A liquid biopsy minimal residual disease (MRD) platform based on circulating tumour DNA (ctDNA) for cancer detection, monitoring of recurrence and precision oncology decision-making.

Genomic Screening & Liquid Biopsy Tests: Non-invasive blood-based genomic screening to detect risk markers for cancers and enable early diagnosis or monitoring of disease status.

Chemical Raw-Material Supply & Industrial Chemicals: Through its subsidiary Chemrex Corporation, BGLC deals in chemical raw materials for industrial and medical manufacturing in Southeast Asia.

Contract Development & Manufacturing Services (planned/expanding): Under its growth strategy, BGLC aims to build CDMO capabilities — including biologics process development, assay manufacturing, quality-systems upgrades and manufacturing capacity — to support regional demand for high-value bioprocessing and diagnostics supply chains.

BioNexus Gene Lab is pursuing a diversified biotechnology and diagnostics strategy, combining precision oncology tests with ambitions for broader CDMO and supply-chain services in Southeast Asia. With its VitaGuard MRD platform, genomic diagnostics portfolio and planned manufacturing capabilities, the company seeks to address growing regional need for accessible, affordable molecular diagnostics and high-quality bioprocessing services. As BGLC advances its business transformation, its integrated model may position it to serve both clinical diagnostics and biologics manufacturing markets in the region.